Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

In February 2025, Teva Pharmaceuticals ... and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s ...

AMSTERDAM, Feb. 20, 2025 (GLOBE NEWSWIRE) -- New research by Teva Pharmaceuticals Europe shows ... The research shows that for most critical generic medicines' supply (e.g. cardiology, oncology ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

And our product launches ... capital within Teva to drive what has been a significant turnaround at this company in two years. We've been able to actually drive the top line while managing the ...

Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries ... feel like you missed the boat in buying the most successful stocks? Then you’ll want ...

The fund owned 504,392 shares of the company’s stock after selling 88,801 shares during the quarter. abrdn plc’s holdings in Teva Pharmaceutical Industries were worth $11,258,000 at the end of ...